Androgen Deprivation Therapy and Definitive Radiotherapy for Prostate Cancer

被引：3
作者：
Mendenhall, William M. [1 ,2 ]
Henderson, Randal H. [2 ]
Hoppe, Bradford S. [2 ]
Nichols, Romaine Charles [2 ]
Mendenhall, Nancy P. [2 ]
机构：
[1] Univ Florida, Coll Med, Dept Radiat Oncol, Gainesville, FL USA
[2] Univ Florida, Proton Therapy Inst, Jacksonville, FL USA
来源：
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2013年 / 36卷 / 05期
关键词：
prostate cancer; adjuvant androgen deprivation therapy; radiotherapy; III RANDOMIZED-TRIAL; CARDIOVASCULAR-DISEASE; RADIATION-THERAPY; SHORT-TERM; BIOCHEMICAL FAILURE; EXTERNAL-BEAM; RTOG; 85-31; MEN; SUPPRESSION; SURVIVAL;
D O I：
10.1097/COC.0b013e31821dee4e
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Adjuvant androgen deprivation therapy (ADT) improves outcomes of patients receiving definitive radiotherapy (RT) for local-regionally advanced prostate cancer. However, patients in most randomized trials had more advanced disease than observed in many practices and were treated with suboptimal RT doses. Although data are conflicting, long-term ADT likely has adverse side-effects in patients with comorbidities. We recommend 6 months of ADT monotherapy with gonadotropin-releasing hormone agonist and RT for patients with high-risk prostate cancer (T2c, Gleason Score 8 to 10, and/or prostate-specific antigen 20 ng/mL) with minimal or no comorbidities. Adjuvant ADT for unfavorable intermediate-risk patients with a Gleason Score of 4+3=7 is also reasonable.
引用
收藏
页码：530 / 534
页数：5
相关论文
共 37 条
  • [1] IS BIOCHEMICAL RESPONSE MORE IMPORTANT THAN DURATION OF NEOADJUVANT HORMONE THERAPY BEFORE RADIOTHERAPY FOR CLINICALLY LOCALIZED PROSTATE CANCER? AN ANALYSIS OF THE 3-VERSUS 8-MONTH RANDOMIZED TRIAL
    Alexander, Abraham
    Crook, Juanita
    Jones, Stuart
    Malone, Shawn
    Bowen, Julie
    Truong, Pauline
    Pai, Howard
    Ludgate, Charles
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 76 (01): : 23 - 30
  • [2] Impact of Androgen Deprivation Therapy on Cardiovascular Disease and Diabetes
    Alibhai, Shabbir M. H.
    Duong-Hua, Minh
    Sutradhar, Rinku
    Fleshner, Neil E.
    Warde, Padraig
    Cheung, Angela M.
    Paszat, Lawrence F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (21) : 3452 - 3458
  • [3] Ten year results of long term adjuvant androgen deprivation with Goserelin in patients with locally advanced prostate cancer treated with radiotherapy:: A phase III EORTC study
    Bolla, M.
    Collette, L.
    Van Tienhoven, G.
    Warde, P.
    Dubois, J. B.
    Mirimanofl, R. O. M.
    Storme, G.
    Bernier, J.
    Kuten, A.
    Pierart, M.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S30 - S31
  • [4] Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial
    Bolla, M
    Collette, L
    Blank, L
    Warde, P
    Dubois, JB
    Mirimanoff, RO
    Storme, G
    Bernier, J
    Kuten, A
    Sternberg, C
    Mattelaer, J
    Torecilla, JL
    Pfeffer, JR
    Cutajar, CL
    Zurlo, A
    Pierart, M
    [J]. LANCET, 2002, 360 (9327) : 103 - 108
  • [5] Duration of Androgen Suppression in the Treatment of Prostate Cancer
    Bolla, Michel
    de Reijke, Theodorus M.
    Van Tienhoven, Geertjan
    Van den Bergh, Alphonsus C. M.
    Oddens, Jorg
    Poortmans, Philip M. P.
    Gez, Eliahu
    Kil, Paul
    Akdas, Atif
    Soete, Guy
    Kariakine, Oleg
    Van der Steen-Banasik, Elsbietha M.
    Musat, Elena
    Pierart, Marianne
    Mauer, Murielle E.
    Collette, Laurence
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (24) : 2516 - 2527
  • [6] Does Hormone Treatment Added to Radiotherapy Improve Outcome in Locally Advanced Prostate Cancer? Meta-Analysis of Randomized Trials
    Bria, Emilio
    Cuppone, Federica
    Giannarelli, Diana
    Milella, Michele
    Ruggeri, Enzo Maria
    Sperduti, Isabella
    Pinnaro, Paola
    Terzoli, Edmondo
    Cognetti, Francesco
    Carlini, Paolo
    [J]. CANCER, 2009, 115 (15) : 3446 - 3456
  • [7] The Use of Zoledronic Acid in Men Receiving Androgen Deprivation Therapy for Prostate Cancer With Severe Osteopenia or Osteoporosis
    Campbell, Steven C.
    Bhoopalam, Nirmala
    Moritz, Thomas E.
    Pandya, Mona
    Iyer, Padmini
    VanVeldhuizen, Peter
    Ellis, Nancy K.
    Thottapurathu, Lizy
    Garewal, Harinder
    Warren, Stuart R.
    Friedman, Nicholas
    Reda, Domenic J.
    [J]. UROLOGY, 2010, 75 (05) : 1138 - 1143
  • [8] FINAL REPORT OF MULTICENTER CANADIAN PHASE III RANDOMIZED TRIAL OF 3 VERSUS 8 MONTHS OF NEOADJUVANT ANDROGEN DEPRIVATION THERAPY BEFORE CONVENTIONAL-DOSE RADIOTHERAPY FOR CLINICALLY LOCALIZED PROSTATE CANCER
    Crook, Juanita
    Ludgate, Charles
    Malone, Shawn
    Perry, Gad
    Eapen, Libni
    Bowen, Julie
    Robertson, Susan
    Lockwood, Gina
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 73 (02): : 327 - 333
  • [9] Androgen suppression and radiation vs radiation alone for prostate cancer - A randomized trial
    D'Amico, Anthony V.
    Chen, Ming-Hui
    Renshaw, Andrew A.
    Loffredo, Marian
    Kantoff, Philip W.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 299 (03): : 289 - 295
  • [10] INTERVAL TO TESTOSTERONE RECOVERY AFTER HORMONAL THERAPY FOR PROSTATE CANCER AND RISK OF DEATH
    D'Amico, Anthony V.
    Chen, Ming-Hui
    Renshaw, Andrew A.
    Loffredo, Marian
    Kantoff, Philip W.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (01): : 10 - 15
1234